Provided by Tiger Trade Technology Pte. Ltd.

Merck

105.66
+5.265.24%
Pre-market: 105.46-0.2000-0.19%04:20 EST
Volume:22.23M
Turnover:2.32B
Market Cap:262.25B
PE:13.98
High:105.84
Open:100.73
Low:100.71
Close:100.40
52wk High:105.84
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:1.04
T/O Rate:0.90%
Dividend:3.24
Dividend Rate:3.07%
EPS(TTM):7.56
EPS(LYR):6.76
ROE:39.49%
ROA:13.76%
PB:5.06
PE(LYR):15.63

Loading ...

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Dow Jones
·
Nov 19

Merck Is Maintained at Hold by Deutsche Bank

Dow Jones
·
Nov 19

Stock Track | Merck Soars 5% as Winrevair Succeeds in Key Pulmonary Hypertension Trial

Stock Track
·
Nov 19

Merck Raises Quarterly Dividend to $0.85 From $0.81 a Share, Payable Jan. 8, 2026, to Shareholders of Record Dec. 15

MT Newswires Live
·
Nov 19

Merck raises quarterly dividend to 85c from 81c per share

TIPRANKS
·
Nov 19

Merck & Co Inc - Announces Quarterly Dividend of $0.85 per Share

THOMSON REUTERS
·
Nov 19

Press Release: Merck Announces First-Quarter 2026 Dividend

Dow Jones
·
Nov 19

Merck (MRK.US) Rises Over 4% as Winrevair Succeeds in Mid-Stage Lung Disease Trial

Stock News
·
Nov 18

Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era -- Barrons.com

Dow Jones
·
Nov 18

Merck & Co Shares Rise 1% After Lung Disease Treatment Winrevair Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
Nov 18

BUZZ-U.S. STOCKS ON THE MOVE-Cloudflare, Legence, Lumentum

Reuters
·
Nov 18

BUZZ-Merck rises after lung disease drug meets main goal in mid-stage study

Reuters
·
Nov 18

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Nov 18

Merck Shares Rise 3.4% Premarket After Its Lung Disease Treatment Winrevair Meets Primary Endpoint in Mid-Stage Study

THOMSON REUTERS
·
Nov 18

S&P 500 Futures Drop In Premarket Trading; James Hardie Industries, Amer Sports Lead

Dow Jones
·
Nov 18

Citi Sticks to Their Hold Rating for Merck & Company (MRK)

TIPRANKS
·
Nov 18

Merck’s WINREVAIR Meets Primary Endpoint in Phase 2 Pulmonary Hypertension Study

Reuters
·
Nov 18

Merck & Co Inc - Winrevair Shows Significant Reduction in Pulmonary Vascular Resistance

THOMSON REUTERS
·
Nov 18

Merck & Co Inc - Winrevair Meets Primary Endpoint in Phase 2 Study

THOMSON REUTERS
·
Nov 18

Merck’s Winrevair™ (Sotatercept-Csrk) Met Primary Endpoint in Phase 2 Cadence Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (Cpcph) Due to Heart Failure With Preserved Ejection Fraction (Hfpef)

THOMSON REUTERS
·
Nov 18